Theme: pharmaceuticals-biotechnology-industry
Applications: Therapeutic Development
Laboratory: IESCSH EA4483
Institutions: UNIVERSITY OF LILLE
Intellectual property: 3 patents
Technology
Using patented non-toxic nanoparticles, Vaxinano offers effective vaccines that can replace or complement commercial products. They can be administered nasally, are adjuvant-free, and are bio-eliminable.
Applications
The vaccine formulations developed using this platform can be administered nasally, as the nanoparticles are able to pass through mucus, or by injection. Vaxinano has achieved two world firsts with an immunotherapeutic treatment for leishmaniasis and an inactivated vaccine against toxoplasmosis.
Benefits
The platform developed not only enables the development of new vaccines and the improvement of existing vaccines (replacement of adjuvants), but also reduces or even replaces the use of antibiotics.
Maturity
Vaxinano is positioned as the first company capable of developing adjuvant-free inactivated vaccines administered nasally with proven efficacy against bacterial, parasitic, and viral diseases.
For more information
Contact your dedicated advisor